Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Specific post-marketing surveillance of pazufloxacin (Pasil®) Clinical efficacy and safety of pazufloxacin administered at a dose of 1,000 mg twice daily
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	non interventional
	Summary	To evaluate the clinical efficacy and safety of pazufloxacin (Pasil®), an injectable antimicrobial, in patients with sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by *Streptococcus pneumoniae* at a dose of 1,000 mg twice daily
Details of study	Interventional drug name	Pazufloxacin Inj.
	Target illness	sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by *Streptococcus pneumoniae*
	Classification name (code) of the investigational drug	624 Synthetic antibacterials
	Administration route	Injection
	Control drug name(code/td)	-
	Classification name (code) of the investigational drug	-
	Administration route	-
	Objectives of the study	To evaluate the efficacy and safety
	Study phase	Other
	Study design	Post-marketing surveillance study
	Inclusion Criteria	1. Target disease: sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by *Streptococcus pneumoniae* 2. Age: 15 years of age and older 3. Gender : Both 4. Patients administered at a dose of 1,000 mg twice daily 5. Others
	Outcome	Efficacy and safety
	Study status	Completed
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Data Science and Administration Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn